Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Shares Down 5.5% – Here’s What Happened

by · The Cerbat Gem

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA – Get Free Report) was down 5.5% during mid-day trading on Friday. The stock traded as low as $20.00 and last traded at $20.12. 7,982 shares changed hands during mid-day trading, a decline of 98% from the average daily volume of 426,424 shares. The stock had previously closed at $21.28.

Wall Street Analyst Weigh In

DMRA has been the subject of a number of recent analyst reports. Wedbush restated an “outperform” rating and issued a $40.00 price objective on shares of Damora Therapeutics, Inc. Common Stock in a report on Tuesday. Guggenheim boosted their price target on Damora Therapeutics, Inc. Common Stock from $40.00 to $60.00 and gave the stock a “buy” rating in a research note on Friday, September 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a report on Monday, September 14th. Jefferies Financial Group started coverage on Damora Therapeutics, Inc. Common Stock in a research report on Monday, July 27th. They set a “buy” rating and a $50.00 price objective on the stock. Finally, TD Cowen upgraded Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a report on Monday, August 24th. Three research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $46.50.

View Our Latest Report on Damora Therapeutics, Inc. Common Stock

Damora Therapeutics, Inc. Common Stock Stock Down 1.7%

The company has a market cap of $1.23 billion, a PE ratio of -5.90 and a beta of 1.43. The company’s fifty day moving average is $27.58 and its 200-day moving average is $26.11.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA – Get Free Report) last announced its earnings results on Monday, August 10th. The company reported ($0.39) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.06. Equities research analysts expect that Damora Therapeutics, Inc. Common Stock will post -2.06 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO Jennifer Jarrett bought 12,500 shares of the stock in a transaction on Friday, September 25th. The shares were bought at an average price of $20.23 per share, with a total value of $252,875.00. Following the completion of the acquisition, the chief executive officer owned 512,500 shares in the company, valued at $10,367,875. The trade was a 2.50% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.40% of the company’s stock.

Institutional Investors Weigh In On Damora Therapeutics, Inc. Common Stock

Hedge funds and other institutional investors have recently made changes to their positions in the business. Braidwell LP purchased a new position in shares of Damora Therapeutics, Inc. Common Stock in the second quarter worth approximately $42,146,000. Seven Fleet Capital Management LP purchased a new stake in Damora Therapeutics, Inc. Common Stock during the second quarter valued at approximately $7,398,000. Squarepoint Ops LLC purchased a new stake in Damora Therapeutics, Inc. Common Stock during the second quarter valued at approximately $303,000. Finally, Arizona State Retirement System bought a new position in Damora Therapeutics, Inc. Common Stock in the second quarter worth approximately $260,000. Hedge funds and other institutional investors own 14.20% of the company’s stock.

About Damora Therapeutics, Inc. Common Stock

(Get Free Report)

Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.

Read More